Recruiting PHASE3 INTERVENTIONAL 2-arm NCT04602754

Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

Sponsor: EMS

Conditions Dyslipidemia Associated With Type II Diabetes Mellitus

Interventions BERLIM 25/20 ASSOCIATION BERLIM 25/20 ASSOCIATION PLACEBO EMPAGLIFLOZIN EMPAGLIFLOZIN PLACEBO ROSUVASTATIN CALCIUM ROSUVASTATIN CALCIUM PLACEBO

Updated 7 times since 2020 Last updated: Dec 1, 2025 Started: Dec 1, 2023 Primary completion: May 31, 2026 Completion: Sep 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Dyslipidemia Associated With Type II Diabetes Mellitus, this trial is actively recruiting participants. The trial is conducted by EMS and has accumulated 7 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Recruiting PHASE3
Sep 2024 — Jan 2026 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2022 — Mar 2024 [monthly]

Not Yet Recruiting PHASE3

▶ Show 2 earlier versions

Jan 2021 — Sep 2022 [monthly]

Not Yet Recruiting PHASE3
Nov 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Data source: EMS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Campinas, Brazil